STAT+: New data on Eli Lilly’s ‘triple-G’ drug leave open questions on heart benefit

Data ReadoutMixedretatrutideNegative

AI Analysis

Summary

Eli Lilly's retatrutide (triple-G drug) failed to demonstrate significant cardiovascular benefit on secondary endpoints, with no significant reduction in major adverse cardiovascular events including death, heart attack, or stroke.

Clinical Trial Data

Outcome Details

Secondary endpoints on major cardiovascular events did not show significant reduction in death, heart attack, or stroke risk

Importance:6/10

Sentiment:

-0.30

cardiovascular safetysecondary endpointsclinical trial data

Related Companies

$LLY

Read the original article

Published by STAT News on July 23, 2026 10:45 AM

Read Original